Shares of Day One Biopharmaceuticals Inc. (DAWN) are skyrocketing in Wednesday's pre-market trading, surging by 8.29% following the release of robust Q3 2025 earnings and a reiterated Buy rating from a prominent analyst. This significant uptick reflects growing investor confidence in the biopharmaceutical company's financial performance and future prospects.

Day One Biopharmaceuticals, which specializes in developing targeted therapies for genomically defined cancers, reported its third-quarter results after Tuesday's market close. While specific figures were not disclosed, the earnings report appears to have substantially exceeded market expectations, fueling optimism about the company's financial health and growth trajectory.

Adding to the positive sentiment, H.C. Wainwright analyst Andres Y. Maldonado reaffirmed a Buy rating on Day One Biopharmaceuticals early Wednesday. Although the exact price target was not revealed, this endorsement from a respected financial institution has likely contributed to the stock's pre-market rally. The analyst's continued confidence in DAWN suggests potential upside for the company's shares, encouraging investors to buy in before the regular trading session begins.